Aeglea Biotherapeutics develops engineered human enzymes that degrade specific amino acids to address inborn errors of metabolism and to target abnormal amino acid metabolism in tumors. Its lead candidate, AEB1102 (optimized human Arginase I), is being developed as an enzyme replacement therapy for hyperargininemia and as a systemic arginine‑depleting cancer therapy. The company expected AEB1102 to enter Phase I/II clinical proof‑of‑concept studies as early as the second half of 2015 for both indications. Three additional preclinical candidates include AEB4104 (homocystine degradation for homocystinuria), AEB3103 (cysteine/cystine degradation to increase oxidative stress for hematologic and solid malignancies) and AEB2109 (methionine degradation for solid tumors). Proceeds from the recent financing will support clinical advancement of the lead program and preclinical development of the pipeline. Aeglea was founded in 2013 based on engineered enzymes invented in George Georgiou’s laboratory at The University of Texas at Austin. Aeglea BioTherapeutics is an Austin, Texas–based early-stage drug development company focused on novel cancer treatments. It is developing three drugs invented at the University of Texas that degrade certain amino acids in the circulation to exploit cancer’s metabolic vulnerability and selectively kill tumors. The company is led by President and CEO David G. Lowe, PhD, and is working in partnership with Dr. George Georgiou of UT Austin. Aeglea joined the Austin Technology Incubator (ATI) at the IC2 Institute, University of Texas at Austin. It says the recent financing will fund growth, hiring, research and manufacturing for its lead drug and preparation for the first phase of clinical trials.

Total raised

$56M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2015